The Federal Food and Drug Administration (FDA) wants to know what you think about CBD.
The agency is currently seeking public input at Regulations.Gov on the therapeutic ability and abuse liability of several controlled substances, including CBD – formally known as cannabidiol.
Comments will be used to help inform the FDA ahead of its official response to the World Health Organization, which is considering placing certain substances within their international drug scheduling code.
Despite its non-psychoactive nature, CBD is classified as a Schedule I controlled substance by the U.S. Drug Enforcement Administration – alongside THC, LSD and heroin.
Seventeen states currently recognize CBD as a therapeutic substance, while the head of the U.S. National Institute on Drug Abuse has acknowledged that it is a “safe drug with no addictive effects.”
The FDA will accept comments on CBD until Sept. 13, 2017. More information on submitting your comments can be found here.
h/t NORML Blog